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Abstract. 
 
Melanocyte differentiation characterized by 
an increased melanogenesis, is stimulated by 
 
a
 
-melano-
cyte–stimulating hormone through activation of the 
cAMP pathway. During this process, the expression of 
tyrosinase, the enzyme that controls melanin synthesis 
is upregulated. We previously showed that cAMP regu-
lates transcription of the tyrosinase gene through a 
CATGTG motif that binds microphthalmia a transcrip-
tion factor involved in melanocyte survival. Further, 
microphthalmia stimulates the transcriptional activity 
of the tyrosinase promoter and cAMP increases the 
binding of microphthalmia to the CATGTG motif. 
These observations led us to hypothesize that mi-
crophthalmia mediates the effect of cAMP on the ex-
pression of tyrosinase. The present study was designed 
to elucidate the mechanism by which cAMP regulates 
microphthalmia function and to prove our former hy-
pothesis, suggesting that microphthalmia is a key com-
ponent in cAMP-induced melanogenesis. First, we 
showed that cAMP upregulates the transcription of mi-
crophthalmia gene through a classical cAMP response 
element that is functional only in melanocytes. Then, 
using a dominant-negative mutant of microphthalmia, 
we demonstrated that microphthalmia is required for 
the cAMP effect on tyrosinase promoter. These find-
ings disclose the mechanism by which cAMP stimulates 
tyrosinase expression and melanogenesis and empha-
size the critical role of microphthalmia as signal trans-
ducer in cAMP-induced melanogenesis and pigment 
cell differentiation.
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I
 
n
 
 mammals, melanin synthesis or melanogenesis takes
place in melanocytes after differentiation of the non-
pigmented precursor, the melanoblast (Le Douarin,
1982). Three melanocyte-specific enzymes, tyrosinase (Kör-
ner and Pawelek, 1982; Hearing, 1987; Prota, 1988), tyro-
sinase-related protein 1 (TRP1)
 
1
 
 (Jiménez-Cervantes et
al., 1994; Kobayashi et al., 1994), and tyrosinase-related
protein 2 (TRP2) (Barber et al., 1984; Jackson et al., 1992;
Yokoyama et al., 1994
 
a
 
) are involved in this enzymatic
process that converts tyrosine to melanin pigments. The
expression of these enzymes is restricted to melanocytes,
suggesting that their promoters contain regulatory ele-
ments responsible for tissue-specific expression. Sequenc-
ing of tyrosinase, TRP1, and TRP2 promoters has re-
vealed a highly conserved 10-bp motif (GTCATGTGCT)
termed the M-box that plays a key role in the tissue-spe-
cific expression of tyrosinase and TRP1 genes (Lowings
et al., 1992; Ganss et al., 1994; Yokoyama et al., 1994
 
b
 
).
The M-box core motif, CATGTG, is reminiscent of the
CANNTG sequence (E-box), which binds basic-helix-
loop-helix (b-HLH) transcription factor. Recently, a tran-
scription factor belonging to the b-HLH family, named mi-
crophthalmia (Mi) and expressed in a limited number of
tissues such as heart, mast cells, osteoclast precursors, and
melanocytes has been involved in melanocyte survival, de-
velopment, and differentiation (Hodgkinson et al., 1993;
Steingrímsson et al., 1994). Indeed, mutations at the
mouse mi locus lead to coat color dilution, white spotting,
or complete loss of pigmentation (Hodgkinson et al., 1993;
Hughes et al., 1993). Similarly, mutations in the human ho-
mologue of the mouse microphthalmia gene, micro-
phthalmia-associated transcription factor (MITF), has
been linked to abnormal pigmentation observed in
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1. 
 
Abbreviations used in this paper
 
: 
 
a
 
-MSH, 
 
a
 
-melanocyte–stimulating
hormone; b-HLH, basic-helix-loop-helix; CREB, cAMP response element
binding protein; CBP, CREB binding protein; Fsk, forskolin; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; Mi, microphthalmia; MITF,
microphthalmia-associated transcription factor; PKA, protein kinase A;
pNPP, paranitro-phenylphosphate; TRP1 and TRP2, tyrosinase-related
proteins 1 and 2.
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Waardenburg Syndrome type II (Hughes et al., 1994; Tas-
sabehji et al., 1994). Furthermore, studies have shown that
microphthalmia through the binding to M-box strongly
stimulates tyrosinase and TRP1 promoter activities, sug-
gesting that microphthalmia is involved in the tissue-spe-
cific expression of the melanogenic genes (Bentley et al.,
1994; Ganss et al., 1994; Hemesath et al., 1994; Yasumoto
et al., 1994; Yavuzer et al., 1995).
In vivo, melanogenesis is stimulated by ultraviolet radia-
tion of solar light (Ortonne, 1990) and 
 
a
 
-melanocyte–stim-
ulating hormone (
 
a
 
-MSH) (Levine et al., 1991) that in-
crease expression of tyrosinase, the rate-limiting enzyme
in melanin synthesis. In vitro, the melanogenic effects of
 
a
 
-MSH can be mimicked by pharmacological agents such
as forskolin, cholera toxin, and IBMX, indicating that the
cAMP pathway plays an important role in the regulation
of melanogenesis (Wong and Pawelek, 1975; Abdel-Malek
et al., 1987; Jiménez et al., 1988; Hunt et al., 1993; Hunt et al.,
1994; Englaro et al., 1995). Besides its role in melanocyte
survival and tissue-specific expression of the melanogenic
genes, microphthalmia is also involved in the acute regula-
tion of the tyrosinase gene during cAMP-induced melano-
genesis. Indeed, using different construction of the tyrosi-
nase promoter in a luciferase reporter system, we showed
that the M-box plays a key role in the cAMP responsive-
ness of the tyrosinase promoter. Moreover, gel shift exper-
iments showed that forskolin increases microphthalmia
binding to the M-box (Bertolotto et al., 1996) resulting from
an increased microphthalmia expression (Bertolotto et al.,
1998). Taken together, these data led us to propose that
microphthalmia could mediate the effect of cAMP on tyro-
sinase gene expression. However, it remained necessary to
elucidate the mechanism by which cAMP upregulates
microphthalmia expression, and to prove that microph-
thalmia mediates the effect of cAMP on the tyrosinase gene.
In this report, we clearly demonstrate that cAMP elevat-
ing agents increase the level of microphthalmia mRNA
and protein. Furthermore, using a reporter plasmid con-
taining a 2.1-kb fragment 5
 
9
 
 of the transcriptional start site
of the microphthalmia promoter, we showed that cAMP-
elevating agents and protein kinase A (PKA) stimulate
the transcriptional activity of the promoter. Our analysis
of the promoter region revealed that responsiveness to
cAMP is mediated through a CRE consensus motif lo-
cated between 
 
2
 
140 and 
 
2
 
147 bp from the initiation site.
Finally, we showed that a dominant-negative form of mi-
crophthalmia, lacking the NH
 
2
 
-terminal activation do-
main, impaired the stimulation of the tyrosinase promoter
activity induced by cAMP-elevating agents, providing evi-
dence that microphthalmia activity is required for cAMP-
induced stimulation of the tyrosinase promoter. There-
fore, we conclude that cAMP increases microphthalmia
expression, which in turn binds to the tyrosinase promoter
M-box, thereby leading to the stimulation of tyrosinase ex-
pression and melanin synthesis.
 
Materials and Methods
 
Materials
 
Forskolin, 
 
a
 
-melanocyte–stimulating hormone ([Nle
 
4
 
, D-Phe
 
7
 
]-
 
a
 
-MSH),
hydrocortisone, insulin, phorbol 12-myristate 13-acetate (PMA), 
 
p
 
-nitro-
phenyl phosphate (pNPP), NP-40, sodium fluoride, sodium orthovana-
date, 
 
b
 
-glycerophosphate, 4-(2-aminoethyl)-benzene-sulfonyl fluoride
(AEBSF), aprotinin, and leupeptin were purchased from Sigma Chemical
Co. (St. Louis, MO). Klenow fragment and T4 DNA ligase were from Bio-
labs (Beverly, MA). The PGL
 
2
 
-basic vector and the basic (b)-FGF were
from Promega. DME, trypsin, and lipofectamine reagent were from
GIBCO BRL (Gaithersburg, MD), and FCS was from Hyclone Laborato-
ries Inc. (Logan, UT). CREB-1 bZIP (254–327) peptide was from Santa
Cruz Biotechnology (Santa Cruz, CA). The C5 mAb was raised against a
histidine fusion protein expressed from the NH
 
2
 
-terminal Taq-Sac frag-
ment of human MITF cDNA and produces a specific gel mobility super-
shift with microphthalmia, but not with the related proteins TFE3, TFEB,
and TFEC (Weilbaecher et al., 1998). Peroxidase- and FITC-conjugated
anti–mouse antibodies were from Dakopatts (Glostrup, Denmark). Syn-
thetic oligonucleotides were from Oligo (Paris, France) express.
 
Cell Cultures
 
B16/F10 murine melanoma cells and NIH3T3 fibroblast cells were grown
at 37
 
8
 
C under 5% CO
 
2
 
 in DME supplemented with 7% FCS and penicil-
lin/streptomycin (100 U/ml:50 
 
m
 
g/ml). Epidermal cell suspensions were
obtained from foreskins of Caucasoid children by overnight digestion in
PBS containing 0.5% dispase grade II at 4
 
8
 
C, followed by a 1-h digestion
with trypsin/EDTA solution (0.05%:0.02% in PBS) at 37
 
8
 
C. Cells were
grown in MCDB 153 medium supplemented with FCS 2%, 0.4 
 
m
 
g/ml hy-
drocortisone, 5 
 
m
 
g/ml insulin, 16 nM PMA, 1 ng/ml b-FGF, and penicillin/
streptomycin (100 U/ml:50 
 
m
 
g/ml) in a humidified atmosphere containing
5% CO
 
2
 
 at 37
 
8
 
C.
 
Western Blot Assays
 
B16 mouse melanoma cells were grown in six-well dishes with 20 
 
m
 
M for-
skolin or 1 
 
m
 
M 
 
a
 
-MSH for the times indicated on the figure legends. Nor-
mal human melanocytes were grown in six-well dishes for 5 d in MCDB
153 supplemented with 5% FCS, 0.4 
 
m
 
g/ml hydrocortisone, and 5 
 
m
 
g/ml
insulin before stimulation. Then, cells were treated with 20 
 
m
 
M forskolin
or 1 
 
m
 
M 
 
a
 
-MSH for the indicated times. Cells were then lysed in radioim-
munoprecitpitation assay (RIPA) buffer, pH 7.5, containing 10 mM Tris-
HCl, 1% sodium deoxycholate, 1% NP-40, 150 mM NaCl, 0.1% SDS, 5
 
m
 
g/ml leupeptin, 1 mM AEBSF, 100 IU/ml aprotinin, 1 mM NaVO4, 5 mM
NaF, 20 mM 
 
b
 
-glycerophosphate, and 10 mM pNPP. Proteins (20 
 
m
 
g)
were separated on 7.5% SDS–polyacrylamide gels and transferred to a ni-
trocellulose membrane. Microphthalmia protein was detected with the C5
mAb at a 1/10 dilution in saturation buffer and with a secondary peroxi-
dase-conjugated anti–mouse antibody at a 1/3,000 dilution. Protein was vi-
sualized with the enhanced chemiluminescence (ECL) system from Am-
ersham Life Sciences, Inc. (Arlington Heights, IL).
 
Northern Blot Analysis
 
poly(A)
 
1
 
 RNA were isolated from control and forskolin-treated B16
melanoma cells using the mRNA purification kit from Qiagen Inc. (Va-
lencia, CA) (Oligotex™, mRNA). RNA was denatured 5 min at 65
 
8
 
C in a
formamide/formaldehyde mixture, separated by electrophoresis in a 1%
agarose-2.2 M formaldehyde gel, transferred to a nylon membrane (Hy-
bond N.; Amersham Life Sciences, Inc.) in 20
 
3 
 
SSPE, pH 7.7 (3.5 M
NaCl, 0.2 M sodium phosphate, 0.02 M Na
 
2
 
EDTA), and then hybridized
to microphthalmia and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) probe labeling by random priming with 
 
a
 
-[
 
32
 
P]dCTP (Amer-
sham Life Sciences, Inc.). The microphthalmia probe was the 1.3-kb Hind-
III–NotI fragment containing the full open reading frame of micro-
phthalmia (Bertolotto et al., 1996).
 
Construction of the Reporter Plasmids
 
A 2.1-kb fragment 5
 
9
 
 of the transcriptional start site of the MITF gene was
isolated from SpMITF 1, kindly provided by Dr. Shibahara (Tohoku Uni-
versity School, Sendaï, Japan; Fuse et al., 1996). The 2.1-kb BamHI–BanI
(converted to blunt end) fragment was isolated from pBluescript IISK
 
1
 
SpMITF 1 and subcloned into the unique BglII (compatible with BamHI)/
HindIII (converted to blunt end) restriction site of the pGL
 
2
 
 basic vector
(pGL
 
2
 
B), upstream of the luciferase coding sequence (pMI: 
 
2
 
2135/
 
1
 
136).
Cohesive ends were filled in with Klenow fragment. The transcription ini-
tiation site was numbered 
 
1
 
1 according to the report of Fuse et al. (1996).
For the deletion constructs, pMI was first linearized with AvrII, MscI,
AflII, or PstI located in the MITF promoter and filled in with Klenow 
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fragment. The plasmids were then digested by the unique SmaI site of the
pGL
 
2
 
B and self-ligated with T4 DNA ligase, giving, respectively, the fol-
lowing plasmids: pMI
 
D
 
1 (
 
2
 
1,812/
 
1
 
136), pMI
 
D
 
2 (
 
2
 
1,581/
 
1
 
136), pMI
 
D
 
3
(
 
2
 
680/
 
1
 
136), pMI
 
D
 
4 (
 
2
 
387/
 
1
 
136). pMI
 
D
 
5 and pMImCRE were con-
structed with the Transformer™ site-directed mutagenesis kit (CLON-
TECH Laboratories, Inc., Palo Alto, CA). Initially, we introduced a NheI
site (5
 
9
 
-GATATCAACATTTAAGACC-GCTAGCAAACTCGTAGGGC-
TTCC-3
 
9
 
) just below the CRE sequence located between 
 
2
 
147 and 
 
2
 
140
bp upstream from the initiation start site of the microphthalmia gene in
pMI. pMI was then linearized with NheI, filled in with Klenow fragment,
digested by SmaI, and then the plasmid was self-ligated with T4 DNA li-
gase to give pMI
 
D
 
5 (
 
2
 
103/
 
1
 
136). In pMImCRE, the CRE site was mu-
tated with an oligonucleotide that changes the TGACGTCA sequence in
TGGGGTCA (5
 
9
 
-GAAAAAAAGCATGGGGTCAAGCCAGGGG-3
 
9
 
).
The minimal thymidine kinase promoter (
 
2
 
80/
 
1
 
60) was cloned upstream
the luciferase coding sequence in the NheI–BglII sites of pGL
 
2
 
B (pTK).
Double-stranded oligonucleotides corresponding to the microphthalmia
sequence 
 
2
 
136/
 
2
 
153 and containing the CRE motif were then cloned into
the SmaI–SacI sites of the pTK plasmid (pTKCRE). pTKmCRE corre-
sponds to the pTKCRE in which the CRE motif TGACGTCA was con-
verted to TGGGGTCA.
The reporter plasmid containing the 2.2-kb fragment of the mouse tyro-
sinase promoter (pTyro; 
 
2
 
2,236/
 
1
 
59) as well as the cloning of the mi-
crophthalmia coding sequence (Mi) in pCDNA
 
3
 
 expression vector were
described in our previous report (Bertolotto et al., 1996). Mi-
 
D
 
NT con-
taining an inframe deletion extending between amino acids 11 and 704
that delete the NH
 
2
 
-terminal domain was obtained from pCDNA
 
3
 
Mi by
mutagenesis with the following oligonucleotide (5
 
9
 
-GCTGGAAAT-
GCTAGAATACGCAAGAGCATTGGCTAA-3
 
9
 
).
 
Transfections and Luciferase Assays
 
B16 melanoma cells and NIH3T3 fibroblast cells were seeded in 24-well
dishes and transient transfections were performed the following day using
2 
 
m
 
l of lipofectamine and 0.5 
 
m
 
g of total plasmid DNA in a 200 
 
m
 
l final
volume as indicated in figure legends. pCMV
 
b
 
GAL was transfected with
the test plasmids to control the variability in transfection efficiency. 24 h
after transfection, soluble extracts were harvested in 50 
 
m
 
l of lysis buffer
and assayed for luciferase and 
 
b
 
-galactosidase activities. In our conditions,
 
a
 
-MSH, forskolin (Fsk), and PKA increase slightly pCMV
 
b
 
GAL expres-
sion (1.5-, 1.5- and 1.8-fold, respectively). All transfections were repeated
at least five times using different plasmid preparations.
 
In Vitro Transcription/Translation
 
In vitro translation of microphthalmia, Mi-
 
D
 
NT and microphthalmia
mixed with Mi-
 
D
 
NT were carried out using the linked T7 transcription/
translation system from Amersham Life Science, Inc. Microphthalmia and
Mi-
 
D
 
NT translation were monitored using [
 
35
 
S]methionine (Amersham
life Science, Inc.) and SDS-PAGE analysis.
 
Gel Mobility Shift Assay
 
Double-stranded synthetic M-box (5
 
9
 
-GAAAAAGTTAGTCATGTGCTT-
TGCAGAAGA-3
 
9
 
), CRE (5
 
9
 
-AAAGCATGACGTCAAGCCAG-3
 
9
 
) or
mutated CRE (mCRE) (5
 
9
 
-AAAGCATGGGGTCAAGCCAG-3
 
9
 
) were
end labeled with 
 
g
 
-[
 
32
 
P]ATP (Amersham Life Sciences, Inc.) and T4 poly-
nucleotide kinase. In vitro–translated proteins (microphthalmia, Mi-
 
D
 
NT,
microphthalmia, plus Mi-
 
D
 
NT), CREB-1 bZIP (254–327), or nuclear ex-
tracts prepared as previously described (Bertolotto et al., 1998), were pre-
incubated in binding buffer containing 10 mM Tris, pH 7.5, 100 mM NaCl,
1 mM DTT, 1 mM EDTA, 4% glycerol, 80 
 
m
 
g/ml of salmon sperm DNA,
0.1 
 
m
 
g poly (dIdC), 10% FCS, 2 mM MgCl
 
2
 
, and 2 mM spermidine for 15
min on ice. Then, 30,000–50,000 cpm of 32P-labeled probe were added to
the binding reaction for 10 min at room temperature. DNA–protein com-
plexes were resolved by electrophoresis on 5.5% polyacrylamide gel (37.5:1;
acrylamide/bisacrylamide) in TBE buffer (22.5 mM Tris-borate, 0.5 mM
EDTA, pH 8) for 2 h at 150 V.
Results
Stimulation of Microphthalmia Expression by
cAMP-elevating Agents in B16 Melanoma Cells and in
Normal Human Melanocytes
First, we wished to assess short-term effects of Fsk on mi-
crophthalmia expression. In basal conditions, immunoflu-
orescence studies showed, a weak nuclear labeling with an
anti-microphthalmia mAb (Weilbaecher et al., 1998) (Fig.
1). Interestingly, when B16 melanoma cells were incu-
bated 2 h with Fsk, the nuclear labeling was increased and
the maximal effect was obtained after 4 h. Then, after 24 h
with Fsk, the nuclear labeling decreased but remained
clearly above the basal level.
Next, we carried out Western blot experiments with the
anti-microphthalmia mAb in both B16 melanoma cells
(Fig. 2, top panel) and normal human melanocytes (Fig. 2,
bottom panel). Similar results were obtained for both cell
types. In basal conditions, microphthalmia appeared as a
doublet of 55 and 60 kD that have been shown to repre-
sent a MAP kinase–specific phosphorylation of microph-
thalmia, based on two-dimensional tryptic mapping (Heme-
sath et al., 1998). After 3 h, Fsk markedly increased the
level of microphthalmia protein. Maximal expression of
microphthalmia with Fsk treatment was observed between
Figure 1. Forskolin treatment stimulates
microphthalmia gene expression in B16 mouse
melanoma cells. Immunofluorescence labeling
was performed with the anti-microphthalmia
mAb. Unstimulated B16 mouse melanoma
cells (A), B16 mouse melanoma cells stimu-
lated with 20 mM forskolin for 3 h (B), 5 h
(C), and 24 h (D). Bar, 10 mm.The Journal of Cell Biology, Volume 142, 1998 830
3 and 5 h, and then decreased after 24 h consistently with
our findings from the immunofluorescence study. Ad-
ditionally, the physiological melanogenic agent a-MSH
also induced a strong stimulation of microphthalmia ex-
pression after 3 h in both B16 melanoma cells (Fig. 2, top
panel) and normal melanocytes (bottom panel) thereby
demonstrating that cAMP-elevating agents lead to a rapid
induction of microphthalmia expression in both cell types.
Regulation of Microphthalmia Expression in B16 
Melanoma Cells Involves a Transcriptional Mechanism
To investigate the mechanism by which Fsk increases mi-
crophthalmia expression, we first performed a Northern
blot experiment. As shown in Fig. 3 A, top panel, incuba-
tion for 2 or 4 h with Fsk induced a strong increase in mi-
crophthalmia mRNA level (ninefold and eightfold, respec-
tively). Then, the amount of microphthalmia transcripts
decreased after 24 h with Fsk. The loading of each lane
was controlled with a GAPDH probe (Fig. 3 A, bottom
panel). Next, we wished to investigate the effect of cAMP
on the transcriptional activity of the microphthalmia gene
promoter. To accomplish this aim, we studied the effect of
Fsk on a reporter plasmid containing a 2.1-kb fragment of
the microphthalmia promoter upstream of the luciferase
coding sequence (pMI). pMI was transiently transfected in
B16 melanoma cells and exposed to cAMP-elevating
agents for 12 h (Fig. 3 B). a-MSH and Fsk treatment
caused a 7-fold and a 15-fold stimulation, respectively, of
the luciferase activity of pMI. A large stimulation of the
luciferase activity was obtained when pMI was cotrans-
fected with an expression vector encoding the catalytic
subunit of PKA (30-fold). Taken together, these results
demonstrate that cAMP elevating agents regulate mi-
crophthalmia expression through a transcriptional mecha-
nism and show the presence in this part of the promoter of
cis-acting elements accountable for the cAMP sensitivity
of the microphthalmia promoter.
Localization of cis-Regulatory Elements Involved in the 
cAMP Response of the Microphthalmia Promoter
The next series of experiments were undertaken to iden-
tify the elements responsible for the cAMP sensitivity of
the microphthalmia promoter. Hence, we studied the ef-
fects of Fsk on the transcriptional activity of reporter plas-
mids containing various deletions in the 59 flanking region
of the promoter. Luciferase activity of pMI, pMID1
(21,812/1136), pMID2 (21,581/1136), pMID3 (2680/
1136), and pMID4 (2387/1136) was stimulated z20-fold
by Fsk while in the same condition, luciferase activity of
pMID5 (2103/1136) was only stimulated threefold (Fig.
4). Interestingly, the 2.1-kb fragment of the microph-
thalmia promoter contained a CRE consensus sequence
(TGACGTCA) located just upstream of the pMID5 dele-
tion. Mutation of the CRE motif in pMI (pMImCRE)
markedly reduced the stimulation of luciferase activity
(fivefold) in response to Fsk, thus demonstrating the key
role of this CRE motif in the cAMP response of the pMI.
Gel shift assay, using labeled probe corresponding to the
CRE motif of the microphthalmia promoter showed that
purified CREB-1 bZIP bound specifically to this CRE mo-
tif (Fig. 5 A). Furthermore, we also observed a complex
between B16 nuclear extracts and the CRE probe (Fig. 5
B). This complex was totally displaced by an excess of un-
labeled homologous CRE oligonucleotide and was shifted
by an anti-CREB antibody. On the other hand, no binding
was observed between B16 nuclear extracts and the
mCRE probe in which the CRE was mutated. Addition-
ally, transfection experiments showed that the presence of
the microphthalmia promoter CRE motif strongly in-
creased the cAMP sensitivity of the minimal thymidine ki-
nase promoter (5-fold for pTK vs. 27-fold for pTKCRE)
while no increase was observed when the CRE was mu-
tated (4-fold for pTKmCRE) (Fig. 5 C).
Figure 2. cAMP-elevating
agents increases microph-
thalmia expression in B16
mouse melanoma cells and in
normal human melanocytes.
20 mg of proteins from B16
mouse melanoma cells (top
panel) or from normal human
melanocytes (bottom panel), non-stimulated or treated for the indi-
cated times with 20 mM forskolin or 1 mM a-MSH, were subjected
to Western blot analysis using the anti-microphthalmia mAb.
Molecular masses, indicated on the left, are expressed in kD.
Figure 3. cAMP-elevating agents regulate microph-
thalmia expression through a transcriptional mecha-
nism. (A) Northern blot analysis for microphthalmia
and GAPDH mRNA transcripts from B16 cells ex-
posed for the indicated times to 20 mM forskolin.
(B) B16 cells were transfected with 0.35 mg of pMI,
0.1 mg of empty pCDNA3, and 0.05 mg of pCMVb9-
GAL. Then, cells were treated for 12 h with 20 mM
forskolin or 1 mM a-MSH. To study the effects of
PKA expression, B16 cells were transfected with
0.35 mg of pMI, 0.1 mg of pCDNA3 encoding PKA,
and 0.05 mg of pCMVbGAL. Luciferase activity was
normalized by the b-galactosidase activity and the
results were expressed as fold stimulation of the
basal luciferase activity from unstimulated cells.
Data are means 6 SE of five experiments per-
formed in triplicate.Bertolotto et al. Microphthalmia Mediates cAMP Effect of Tyrosinase Gene 831
These results clearly show that the CRE consensus mo-
tif, located between 2147 and 2140 bp upstream of the
initiation start site, plays a pivotal role in the cAMP re-
sponsiveness of the microphthalmia promoter. This CRE
motif binds transcription factors of CREB family and is
sufficient to confer cAMP responsiveness to a minimal
promoter.
Stimulation of the Microphthalmia Promoter
Activity by cAMP-elevating Agents Is Restricted to
B16 Melanoma Cells
The 2.1-kb fragment 59 of the transcriptional start site of
the microphthalmia gene promoter was recently shown to
be preferentially expressed in pigment cells (Fuse et al.,
1996). However, identification of a classical CRE consen-
sus motif as the major cis-regulatory element in the cAMP
sensitivity of the microphthalmia promoter in B16 mela-
noma cells prompted us to assay the cAMP response of
pMI in NIH3T3 fibroblast cells. In NIH3T3 cells, lu-
ciferase activity of pMI as well as the reporter plasmids
containing deletions or mutation was not stimulated by
Fsk treatment (Fig. 6). In contrast, in the same condition, a
CRE-reporter plasmid used as control was stimulated 24-
fold by Fsk. Thus, the CRE (2140/2147) of the mi-
crophthalmia promoter is not functional in NIH3T3 cells,
suggesting the existence of a cell-specific mechanism that
makes the microphthalmia promoter responsive to cAMP
in B16 melanoma cells.
Stimulation of the Tyrosinase Promoter Activity by 
cAMP-elevating Agents Is Mediated by Microphthalmia
To demonstrate that microphthalmia is involved in the
stimulation of the tyrosinase promoter activity by cAMP,
we constructed a dominant-negative form of microph-
thalmia, lacking the NH2-terminal transactivation domain
(Mi-DNT). First, we carried out in vitro transcription/
translation of Mi-DNT to verify the expression of the trun-
cated protein using the intact microphthalmia as control.
In vitro–translated microphthalmia (Mi) gave rise to a sin-
gle band z60 kD and Mi-DNT product was at 30 kD (Fig. 7
A). Next, we performed band shift assay using M-box as
probe. Microphthalmia and Mi-DNT formed a complex
with the M-box. According to their respective molecular
weight, Mi complexes migrated slower compared with the
Mi-DNT complexes. When microphthalmia and Mi-DNT
were mixed in transcription/translation reaction, we ob-
served an intermediate complex corresponding to an het-
erodimer Mi/Mi-DNT bound to the M-box (Fig. 7 B).
Then, transfection experiments were undertaken to study
whether Mi-DNT exerted a dominant-negative effect on
Figure 4. The effect of forskolin on microph-
thalmia promoter activity is mediated by a con-
sensus CRE motif (2147/2140). B16 cells were
transfected with 0.45 mg of pMI, pMID1, pMID2,
pMID3, pMID4, pMID5, or pMImCRE and 0.05
mg of pCMVbGAL. After 12 h with forskolin,
luciferase activity was normalized by the b-galac-
tosidase activity and the results were expressed
as fold stimulation of the basal luciferase activity
from unstimulated cells. Data are means 6 SE of
five experiments performed in triplicate. , indi-
cates the TATA box position.
Figure 5. The CRE motif (2147/2140)
binds CREB and confers cAMP sensitivity
to the minimal thymidine kinase pro-
moter. (A) Gel shift experiments were
performed with CREB-1 bZIP (254–327)
using a labeled oligonucleotide containing
the CRE site of the microphthalmia pro-
moter in control conditions or in presence
of an excess (50-fold) of unlabeled homol-
ogous oligonucleotide. (B) B16 nuclear
extracts from control (2) or forskolin-
treated cells (1) were incubated with the
same labeled CRE probe or with a labeled
oligonucleotide in which the CRE site was
mutated (mCRE). When indicated, reac-
tions were carried out in the presence of
an excess (50-fold) of unlabeled homologous CRE probe or with 0.6 ml of an anti-CREB antibody. (C) B16 cells were transfected with
0.35 mg of pTK, pTKCRE, or pTKmCRE and 0.05 mg of pCMVbGAL. After 12 h with forskolin, luciferase activity was normalized by
the b-galactosidase activity and the results were expressed as fold stimulation of the basal luciferase activity from unstimulated cells.
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wild-type microphthalmia. The luciferase activity of the
tyrosinase promoter, pMT2.2, was stimulated sixfold by
transfection with 0.01 mg of an expression vector encoding
microphthalmia. Cotransfection with Mi-DNT dose-depen-
dently decreased the activation of the tyrosinase promoter
induced by microphthalmia (Fig. 7 C), demonstrating that
this mutant inhibits the activity of microphthalmia.
Finally, to study the role of microphthalmia in the cAMP
responsiveness of the tyrosinase promoter (pMT2.2), we co-
transfected pMT2.2 with increasing amounts of Mi-DNT.
Mi-DNT dose-dependently inhibited the stimulation of the
tyrosinase promoter activity induced by a Fsk treatment
(Fig. 8 A) while Mi-DNT did not significantly impair the
cAMP response of a CRE reporter plasmid (Fig. 8 B). The
same doses of empty plasmid did not affect the stimulation
of the tyrosinase promoter activity by Fsk. These results
indicate that microphthalmia activity is required for the in-
duction of tyrosinase promoter activity by cAMP.
Discussion
To thoroughly dissect the mechanism of cAMP-induced
melanogenesis and melanocyte differentiation, we first as-
sessed the early effect of cAMP on the expression of mi-
crophthalmia, which has been proposed to play a pivotal
role in these processes. Immunofluorescence and Western
blot experiments with anti-microphthalmia antibody show
that cAMP elevating agents lead to a rapid, robust, but
transient increase in microphthalmia protein levels in B16
melanoma cells. Using Western blot analysis, the maximal
effect of Fsk was observed between 3 and 5 h. After 24 h,
we observed a marked decrease in microphthalmia expres-
sion indicating that cAMP has a transient effect on mi-
crophthalmia expression. We previously reported that Fsk
did not increase microphthalmia expression (Bertolotto
et al., 1996), but this observation was made after 48 h of
Fsk treatment. At that time, the effect of Fsk is markedly
reduced compared with shorter exposure times. Further-
more, it should be noted that in the present report, we
used an mAb, whereas our previous observations were
made with a polyclonal antibody that showed a stronger
non-specific labeling. Thus, the time of stimulation with
Fsk and the use of different antibodies easily explain the
results obtained in the present report. Fsk treatment also
increases microphthalmia expression in normal human
melanocytes and the same effect can be obtained with a
Figure 6. The CRE motif do not confer cAMP
sensitivity to microphthalmia promoter in
NIH3T3 fibroblast cells. NIH3T3 fibroblast cells
were transfected with 0.45 mg of pMI, pMID1,
pMID2, pMID3, pMID4, pMID5, pMImCRE, or
CRE-LUC and 0.05 mg of pCMVbGAL. After
12 h with forskolin, luciferase activity was nor-
malized by the b-galactosidase activity and the
results were expressed as fold stimulation of the
basal luciferase activity from unstimulated cells.
Data are means 6 SE of five experiments per-
formed in triplicate. , indicates the TATA box
position.
Figure 7. Mi-DNT, a form of microph-
thalmia lacking the NH2-terminal transacti-
vation domain, exerts dominant-negative
effects on the wild-type microphthalmia.
(A) Microphthalmia and Mi-DNT were in
vitro translated in the presence of
[35S]methionine, and then analyzed by gel
electrophoresis. Molecular masses, indi-
cated on the left, are expressed in kD. (B)
For gel shift assay, 2 ml of in vitro–trans-
lated microphthalmia, Mi-DNT, or mi-
crophthalmia plus Mi-DNT were incubated
with labeled tyrosinase M-box. *, Wild-type
microphthalmia homodimer; ***, Mi-DNT
homodimer; and **, microphthalmia plus
Mi-DNT heterodimer. Autoradiogram was
exposed overnight at 2808C. (C) B16 cells
were transfected with 0.4 mg of pTyro, 0.01 mg of pCDNA3 encoding microphthalmia, 0.05 mg of pCMVbGAL, and different amounts
of pCDNA3 encoding Mi-DNT. After 24 h, luciferase activity was normalized by the b-galactosidase activity and the results were ex-
pressed as fold stimulation of the basal luciferase activity from unstimulated cells. Data are means 6 SE of five experiments performed
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physiological cAMP-elevating agent, a-MSH, that induces
pigmentation in humans when subcutaneously injected
(Levine et al., 1991). These data suggest that upregulation
of microphthalmia expression is a common regulatory step
in response to cAMP-elevating agents in both B16 mela-
noma cells and normal human melanocytes, thereby dem-
onstrating the physiological relevance of our observations.
Fsk increases the amount of microphthalmia messengers
and the activity of microphthalmia promoter is stimulated
by a-MSH, Fsk, and co-expression of the catalytic subunit
of PKA. Furthermore, deletions and mutations in the mi-
crophthalmia promoter demonstrated that cAMP effects
are mediated through a CRE consensus motif located be-
tween 2147 and 2140 bp from the transcription start site.
This CRE motif binds CREB family proteins and confers
cAMP sensitivity to the minimal thymidine kinase pro-
moter. However, in NIH3T3 fibroblast cells, Fsk does not
stimulate the microphthalmia promoter activity. The lack
of cAMP responsiveness of the microphthalmia promoter
in NIH3T3 cells cannot be explained by a dysfunctional
cAMP pathway component such as PKA, CREB or
CREB binding protein (CBP), since a construct containing
a somatostatin CRE upstream of the minimal thymidine
kinase promoter is activated by Fsk in these cells. Thus, it
appears that the CRE in the microphthalmia promoter is
turned off in fibroblasts while it is made functional in B16
melanoma cells resulting from a cell-specific mechanism
that remains to be elucidated. Taken together, our results
demonstrate that cAMP, through a classical CRE, stimu-
lates microphthalmia gene transcription thereby leading to
an increase in microphthalmia expression. Since mi-
crophthalmia has been shown to strongly transactivate the
tyrosinase promoter, it was tempting to propose that up-
regulation of tyrosinase amount by cAMP is the direct
consequence of the stimulation of microphthalmia expres-
sion. To verify this hypothesis we constructed a mutated
microphthalmia (Mi-DNT) containing a large deletion in
its NH2 terminus part that removes the transcriptional ac-
tivation domain. A similar naturally occurring mutation,
classified as a semidominant mutation, has been found in
the microphthalmia gene of the white spot mice (miws), as
the consequence of an intragenic deletion of exon 2, 3, and
4 (Hodgkinson et al., 1993; Moore, 1995). Mi-DNT inhib-
ited the transactivation of the tyrosinase promoter in-
duced by the wild-type microphthalmia, demonstrating
that Mi-DNT functions as a dominant-negative mutant.
The effect of Mi-DNT can be explained both by the bind-
ing of Mi-DNT/Mi-DNT homodimer to the M-box that
would prevent the binding of wild-type microphthalmia
and by the dimerization of Mi-DNT with the wild-type mi-
crophthalmia resulting in a non-functional heterodimer.
Interestingly, Mi-DNT inhibits the effect of cAMP on
the tyrosinase promoter activity, but affects neither the
cAMP responsiveness of a construct containing one so-
matostatin CRE nor that of the microphthalmia promoter
(data not shown). In agreement with our former hypothe-
sis, we demonstrate that microphthalmia activity is re-
quired for the induction of the tyrosinase gene expression
by cAMP. Noteworthy, upregulation of tyrosinase mes-
sengers cannot be observed before 6 h of treatment with
cAMP elevating agents (Bertolotto et al., 1996; Rungta et
al., 1996) while generally, the effect of cAMP on gene
transcription is much more rapid (1–2 h). Hence, it has
been thought for a long time that the effect of cAMP on
tyrosinase expression was due to tyrosinase messenger sta-
bilization (Ganss et al., 1994) rather than an increase in ty-
rosinase gene transcription. However, the delayed effect
of cAMP on tyrosinase messenger can be explained by a
two-step mechanism that requires first, the accumulation
of microphthalmia then, an increase in tyrosinase gene
transcription.
The cAMP responsiveness of the microphthalmia pro-
moter implies a classical CRE that binds transcription fac-
tors of CREB family. Another noteworthy observation is
that CREB-mediated regulation of transcription requires
an interaction of phosphorylated CREB with the tran-
scriptional coactivator CBP (Chrivias et al., 1993; Arias
et al., 1994; Kwok et al., 1994). Interestingly, expression of
adenovirus E1A oncoprotein in melanocytes abrogates
pigmentation and expression of melanocyte-specific genes
including tyrosinase, TRP1, TRP2, and microphthalmia
(Yavuzer et al., 1995; Halaban et al., 1996). This observa-
tion could be explained by the binding of E1A to CBP
thereby leading to the inhibition of CREB function as pre-
viously described (Arany et al., 1995). Further, microph-
thalmia has been recently reported to interact with CBP
through the CBP2 domain that also binds E1A (Bannister
and Kouzarides, 1995; Sato et al., 1997). Thus, E1A could
prevent microphthalmia and CBP interaction and reduce
the transactivation of the tyrosinase promoter by mi-
crophthalmia. These two mechanisms could participate in
the extinction of the pigmented phenotype of melanocytes
by E1A protein or by another oncoprotein such as SV40
large T antigen (Dooley et al., 1988; Larue et al., 1993; Or-
low et al., 1995). However, extinction of the pigmented
phenotype could involve other pathways, since the interac-
tion of E1A with CBP seems to be dispensable for the ef-
fect of E1A (Halaban et al., 1996).
Microphthalmia is also known to play a key role in the
development of the melanocyte lineage and recent obser-
vations showed that microphthalmia may convert fibro-
Figure 8. Regulation of tyrosinase promoter activity by forskolin
is mediated by microphthalmia. B16 cells were transfected with
(A) 0.4 mg of pTyro or (B) 0.4 mg of a CRE-LUC reporter plas-
mid, 0.05 mg of pCMVbGAL, and different amounts of pCDNA3
encoding Mi-DNT. After 24 h with forskolin, luciferase activity
was normalized by the b-galactosidase activity and the results
were expressed as fold stimulation of the basal luciferase activity
from unstimulated cells. Data are means 6 SE of five experi-
ments performed in triplicate.The Journal of Cell Biology, Volume 142, 1998 834
blasts to cells with melanocyte features (Tachibana et al.,
1996). This protein is detected very early in the roof of the
neural crest and precedes the expression of the melano-
cyte markers, such as TRP2, TRP1, and tyrosinase (God-
ing and Fisher, 1997; Opdecamp et al., 1997). The mecha-
nism that triggers microphthalmia upregulation during
embryogenesis has not been elucidated. It thought that mi-
croenvironmental factors could induce microphthalmia
expression in stem cells of the melanocytes lineage (Lahav
et al., 1996). That these microenvironmental factors act
through the cAMP pathway to upregulate microphthalmia
expression is a fascinating hypothesis that remains to be
explored.
In the present report we have gathered compelling evi-
dence demonstrating that cAMP-elevating agents, through
PKA activation, increase microphthalmia expression, which
in turn stimulates tyrosinase gene expression, thereby
leading to an increase in melanin pigment production.
These findings, demonstrating that microphthalmia acts as
a signal transducer in cAMP-induced melanocyte differen-
tiation, bring information of paramount importance on the
molecular signaling pathway that controls melanogenesis
and pigment cell differentiation.
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